The DOI matches its Crossref record; the references it cites are not checked yet.
Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights
Open accessAbstract
BACKGROUND: Gliomas, particularly IDH-wildtype astrocytomas, remain highly aggressive and resistant to current therapies. Despite advances in molecular classification, effective therapeutic targets are still limited. Consequently, identifying new targets is essential to improve patient survival. PTPN7, a tyrosine phosphatase implicated in MAPK signaling, is known to play roles in various malignancies but remains underexplored in gliomas. This study examines the prognostic significance, spatial distribution, and immune-related functions of PTPN7, aiming to elucidate its potential as a prognostic role and therapeutic target in glioma treatment. MATERIALS AND METHODS: We analyzed PTPN7 mRNA expression in gliomas via TCGA, CGGA, and single-cell RNA sequencing (GSE131928 and GSE89567). Kaplan determined prognostic significance-Meier and uni-/multi-variate Cox survival analyses. Gene set enrichment analysis (GSEA) was used to identify dysregulated pathways, immune signatures, and cell-type enrichments. We also applied CIBERSORT to evaluate the relationships between PTPN7 expression and 12-principal cell states and 22 immune populations. Spatial transcriptomics (Ivy Glioblastoma Atlas, 10 × Genomics Visium) mapped PTPN7 distribution; these findings were corroborated by immunohistochemistry-validated protein expression in 70 cases. RESULTS: Pan-cancer analysis revealed PTPN7 overexpression in multiple malignancies, including glioma. Notably, PTPN7 was significantly elevated in IDH-wildtype astrocytomas, correlating with higher tumor grades and poorer overall survival. GSEA indicated that high PTPN7 is linked to T-cell differentiation, macrophage/monocyte activation, and dendritic cell-associated pathways. Both immune deconvolution and single-cell analyses showed that PTPN7 positively correlates with myeloid series and T-cell populations, supported by additional GSEA findings. In the Ivy dataset and spatial transcriptomics, PTPN7 was concentrated in peri-necrotic, cellular tumor, and slightly lower in the infiltrating border regions, consistent with immune interaction sites. Immunohistochemical data further demonstrated high PTPN7 expression tracks with increased tumor grade, reaching statistical significance in IDH-wildtype astrocytomas and confirming its clinical relevance. CONCLUSION: This study positions PTPN7 as a prognostic biomarker and immune modulator in gliomas, particularly IDH-wildtype astrocytomas. Its expression correlates with tumor aggressiveness and immune infiltration, potentially driving glioma progression. Targeting PTPN7 may disrupt immune evasion and support tumor eradication, indicating a promising therapeutic avenue in immunotherapy-based strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Fig. 5 Immunohistochemical quantification of PTPN7 in normal brain and gliomas. A TCGA proteomic analysis confirmed elevated PTPN7 expression in glioblastoma over normal tissue. B Summary table of PTPN7 density (mean ± SD) in normal tissue (n = 11) and IDH‐wildtype (n = 37) and IDH‐mutant glioma (n = 22). C Representative tissue cores (H&E, low‐power IHC, automated machine quantification, and high‐power IHC) reveal immunostaining ranging from 0.17 to 48.93. (Black = background [B], Blue = Tissue [T], Yellow “+” = staining cells). D, E Box plots of PTPN7 density by WHO grade for IDH‐wildtype or IDH‐mutant astrocytoma. F, G Comparisons of normal, low‐grade, and high‐grade groups. Elevated PTPN7 correlates with tumor grade in the IDH wildtype group but is obscure in the IDH mutant group](https://figures.cochat.ai/paper-figures/759dade797bb42049c2c81f811666977/dissecting-ptpn7driven-aggressiveness-in-idhwildtype-astrocytomas-multiomics-figure-5.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 40 · Cited by 4
Metadata
- Authors
- Liu, T., Lin, Y.-C., Chang, P.-C., Hueng, D.-Y., & Li, Y.-F.
- Affiliations
- Tri-Service General Hospital (TW)
- Taoyuan Armed Forces General Hospital (TW)
- National Defense Medical Center (TW)
- Corresponding author
- Li, Yao-Feng
- Venue
- Discover Oncology
- Published
- 2025-05-24
- Volume
- 16
- Issue
- 1
- Pages
- 914-914
- ISSN
- 2730-6011 (ISSN-L)
- PMC
- PMC12103406
- OpenAlex
- W4410708929
- Cited by
- 4
- References
- 40
- Citations by year
- 2026: 2 · 2025: 2
- FWCI
- 2.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- Discover Oncology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tri-Service General Hospital (TSGH-E-111269)
- National Science and Technology Council (113-2321-B-016 -005, 111-2314-B-016 -064 -MY3)
- Taipei, Taichung, Kaohsiung Veterans General Hospital, Tri-Service General Hospital, Academia Sinica Joint Research Program (VTA113-T-4-2)
- Ministry of National Defense Medical Affairs Bureau (MND-MAB-D-113167)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- glioma, protein tyrosine phosphatase, MAPK signaling, prognostic factors, therapeutic target, tumor immune microenvironment, myeloid cells, T cell differentiation, tumor grade, spatial transcriptomics, pan-cancer analysis, overall survival, tumor necrosis, tumor-infiltrating immune cells, cell of origin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights. https://app.cochat.ai/papers/10.1007/s12672-025-02662-5
- The paper
- Liu, T., Lin, Y.-C., Chang, P.-C., Hueng, D.-Y., & Li, Y.-F. (2025). Dissecting PTPN7‐driven aggressiveness in IDH‐wildtype astrocytomas: multi‐omics, clinical validation, and spatial transcriptomics for prognostic insights. Discover Oncology. https://doi.org/10.1007/s12672-025-02662-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.